Glaucoma

FDA accepts premarket approval application for DE-128 microshunt

The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review, according to a press release from Santen Pharmaceutical Co.

The microshunt is an investigational surgical glaucoma implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications.

Read the full press release…

Read More


featured stories

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. May 20, 2020

Perceived Medication Volume Impacts Satisfaction in Patients with Glaucoma

Patients with glaucoma were more satisfied with their treatment when receiving the highest volume of medication, indicating a correlation between perceived medication volume and satisfaction, according to a poster presented at the American Society of Cataract and Refractive Surgery (…

View All

Journal Scan

  1. Jun 05, 2020

What day of the week is IOP lowest?

Intraocular pressure (IOP) varies by season with significantly higher IOPs noted in winter compared with summer months, according to a study published in the British Journal of Ophthalmology. In addition, researcher found IOP to be lower on Friday…

View All

Trending Topics

  1. Jul 07, 2020

FDA accepts premarket approval application for DE-128 microshunt

The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review, according to a press release from Santen Pharmaceutical Co.

The microshunt is an investigational surgical glaucoma implant…

View All

Resources